These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27594823)

  • 1. Pramipexole Impairs Stimulus-Response Learning in Healthy Young Adults.
    Gallant H; Vo A; Seergobin KN; MacDonald PA
    Front Neurosci; 2016; 10():374. PubMed ID: 27594823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa impairs probabilistic reversal learning in healthy young adults.
    Vo A; Seergobin KN; Morrow SA; MacDonald PA
    Psychopharmacology (Berl); 2016 Jul; 233(14):2753-63. PubMed ID: 27241710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of levodopa on stimulus-response learning versus response selection in healthy young adults.
    Vo A; Seergobin KN; MacDonald PA
    Behav Brain Res; 2017 Jan; 317():553-561. PubMed ID: 27743941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent effects of age and levodopa on reversal learning in healthy volunteers.
    Vo A; Seergobin KN; MacDonald PA
    Neurobiol Aging; 2018 Sep; 69():129-139. PubMed ID: 29894903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic medication impairs feedback-based stimulus-response learning but not response selection in Parkinson's disease.
    Vo A; Hiebert NM; Seergobin KN; Solcz S; Partridge A; MacDonald PA
    Front Hum Neurosci; 2014; 8():784. PubMed ID: 25324767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate.
    Drijgers RL; Verhey FR; Tissingh G; van Domburg PH; Aalten P; Leentjens AF
    J Neurol Sci; 2012 Sep; 320(1-2):121-6. PubMed ID: 22824349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers.
    Yang XQ; Glizer D; Vo A; Seergobin KN; MacDonald PA
    Front Hum Neurosci; 2016; 10():523. PubMed ID: 27803657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Taste Recognition Following Subacute Treatment With The Dopamine D2/D3 Receptor Agonist Pramipexole in Healthy Volunteers.
    Kaltenboeck A; Halahakoon DC; Harmer CJ; Cowen P; Browning M
    Int J Neuropsychopharmacol; 2022 Sep; 25(9):720-726. PubMed ID: 35605609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic therapy affects learning and impulsivity in Parkinson's disease.
    Hiebert NM; Seergobin KN; Vo A; Ganjavi H; MacDonald PA
    Ann Clin Transl Neurol; 2014 Oct; 1(10):833-43. PubMed ID: 25493274
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Robertson BD; Al Jaja AS; MacDonald AA; Hiebert NM; Tamjeedi R; Seergobin KN; Schwarz UI; Kim RB; MacDonald PA
    Front Neurol; 2018; 9():693. PubMed ID: 30186226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical studies of pramipexole: clinical relevance.
    Hubble JP
    Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms Underlying Dopamine-Induced Risky Choice in Parkinson's Disease With and Without Depression (History).
    Timmer MHM; Sescousse G; Esselink RAJ; Piray P; Cools R
    Comput Psychiatr; 2018 Feb; 2():11-27. PubMed ID: 30090860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive states influence dopamine-driven aberrant learning in Parkinson's disease.
    Cavanagh JF; Mueller AA; Brown DR; Janowich JR; Story-Remer JH; Wegele A; Richardson SP
    Cortex; 2017 May; 90():115-124. PubMed ID: 28384481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic Medication Modulates Learning from Feedback and Error-Related Negativity in Parkinson's Disease: A Pilot Study.
    Volpato C; Schiff S; Facchini S; Silvoni S; Cavinato M; Piccione F; Antonini A; Birbaumer N
    Front Behav Neurosci; 2016; 10():205. PubMed ID: 27822182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.